We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




FISH Method Developed for Analyzing Immune Response

By LabMedica International staff writers
Posted on 30 May 2017
Researchers have developed a method to analyze hundreds of thousands of cells at once using FISH-Flow for concurrent detection of mRNA and protein markers in single cells using fluorescence in situ hybridization (FISH) and flow cytometry. More...
The new protocol currently evaluates immune responses and could lead to faster and more accurate diagnoses of illnesses, including tuberculosis (TB) and cancers.

Researchers at Rutgers University developed the protocol to evaluate multitudes of cells at once for telltale mRNA species and proteins. The procedure currently provides an opportunity to observe how multiple kinds of immune cells are responding to a foreign substance (e.g. antigen), making it possible to detect the presence of disease earlier.

"This new process allows us to see how individual immune cells are reacting in real time without using artificial reagents that alter what the cells are doing when they respond to a foreign substance," said Maria Laura Gennaro, a professor at Rutgers' Public Health Research Institute (PHRI), who led development of the method with senior colleagues Yuri Bushkin, Richard Pine, and Sanjay Tyagi at PHRI. As the protocol could be used to identify indicators of other illnesses, they plan to study applying it to early diagnosis and treatment of various infectious and non-infectious lung diseases and certain cancers.

"This powerful diagnostic technology exploits a person's own immune system to assess their potential for developing a wide range of acute and chronic diseases – including those caused by infectious agents and those resulting from host dysfunction like cancer, asthma, or autoimmune disorders," said David Perlin, executive director of Rutgers’ PHRI.

The procedure can be particularly useful in finding ways to help identify people who are predisposed to developing TB, making it possible to treat them and help reduce the spread of the disease. Nearly 2 billion people worldwide are afflicted with latent TB, but many never develop full-blown TB. Currently, the only way to determine if latent TB is present is through skin and blood tests for immunological response to TB antigens. However, treatment is not widely offered to people with latent TB due to the prohibitive cost.

"If you can have a method that helps you determine who among the people who are latently affected by TB are predisposed to illness, you can target treatment of latent TB to those people and the risk of spread is reduced," Prof. Gennaro said.

The procedure detailed also includes a semi-automated version developed by Gennaro's research group in collaboration with engineers at San Jose, California-based BD Biosciences that makes the method faster and highly reproducible for clinical applications.

The study, by Arrigucci R et al, was published May 18, 2017, in the journal Nature Protocols.


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.